title: [SPECTRUM OF ANTIBIOTIC RESISTANCE AND PREVALENCE OF OXA-CARBAPENEMASES AMONG ACINETOBACTER BAUMANNII STRAINS, ISOLATED FROM PATIENTS OF SURGICAL AND REANIMATION DEPARTMENTS IN MOSCOW].
abstract: OBJECTIVE
  Characterize spectrum of antibiotics resistance of Acinetobacter baumannii strains, isolated from patients of 8 surgical and reanimation departments of 3 medical institution of Moscow, and determine molecular-genetic mechanisms of stability of their carbapenem-resistant forms.
  
  
  METHODS
  95 strains of A. baumannii, isolated from patients of reanimation and surgical departments of Moscow in 2012-2014, were studied. Sensitivity of strains to antibiotics was tested phenotypically according to recommendations of EUCAST. The presence of VIM, IMP, OXA-23, OXA-40, OXA-48, OXA-58 and NDM genes in the studied strains was determined by polymerase chain reaction in real time.
  
  
  RESULTS
  86.3% of strains turnedout to be non-sensitive to carbapenems, sensitive--13.7%. 80.0% of strains were non-sensitive to gentamicin, 80.0% of strains--to netilmicin, 94.7% of strains--to ciprofloxacin 2.1%--to colistin. 91.6% of isolates have shown non-sensitivity to members of 2 and more classes of antibiotics, 78.9% of strains--to members of 3 classes. 2 strains were panresistant, 4.2% (4/95) of the isolates were sensitive to all the classes of antibiotics. Metallo-β-lactamases were not detected. Genes of carbapenemases (OXA-23 and/or OXA-40) were detected in 85.3% (81/95) of strains, characterized phenotypically as non-sensitive to carbapenems.
  
  
  CONCLUSIONS
  The results obtained shown an increase of resistance to carbapenems and multiple resistance in clinically significant strains of A. baumannii. Resistance to carbapenems is associated with OXA-23 and OXA-40 genes. The conclusions allow to justify perspectives of introduction of technologies of molecular-genetic testing of antibiotics resistance.
authors.forename: O A
authors.initials: OA
authors.lastname: Kryzhanovskaya
authors.forename: A V
authors.initials: AV
authors.lastname: Lazareva
authors.forename: I V
authors.initials: IV
authors.lastname: Chebotar
authors.forename: Yu A
authors.initials: YA
authors.lastname: Bocharova
authors.forename: N A
authors.initials: NA
authors.lastname: Mayansky
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D015780:Carbapenems / Q000494:pharmacology*; D002648:Child; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D015870:Gene Expression; D006801:Humans; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D009031:Moscow / Q000453:epidemiology; D015995:Prevalence; D060888:Real-Time Polymerase Chain Reaction; D013514:Surgical Procedures, Operative; D001618:beta-Lactamases / Q000235:genetics* / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; C466679:beta-lactamase OXA-23; D001618:beta-Lactamases; C488541:beta-lactamase OXA-40, Acinetobacter baumannii; C063912:carbapenemase